Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29890496 | 1.00 | KDM4E (0.36) | KDM4ERAB9AKMT2ASMN1; SMN2LMNA | |
| SCHEMBL23410593 | 0.85 | HTR4 (0.34) | KDM4ERAB9AKMT2ASMN1; SMN2LMNA | |
| SCHEMBL29890355 | 0.85 | HTR4 (0.34) | KDM4ERAB9AKMT2ASMN1; SMN2LMNA | |
| SCHEMBL29891532 | 0.84 | TSHR (0.37) | KMT2ALMNAPOLBSGMS2 | |
| SCHEMBL23410934 | 0.84 | HDAC6 (0.39) | KDM4ERAB9AKMT2ASMN1; SMN2LMNA | |
| SCHEMBL29890887 | 0.84 | HDAC6 (0.39) | KDM4ERAB9AKMT2ASMN1; SMN2LMNA | |
| SCHEMBL23411359 | 0.84 | TSHR (0.37) | KMT2ALMNAPOLBSGMS2 | |
| SCHEMBL23410883 | 0.82 | LMNA (0.48) | SMN1; SMN2LMNAKCNH2POLBMAPT | |
| SCHEMBL29890195 | 0.82 | LMNA (0.48) | SMN1; SMN2LMNAKCNH2POLBMAPT | |
| SCHEMBL23411245 | 0.78 | LMNA (0.46) | KDM4ESMN1; SMN2LMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | claimed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | claimed |
| WO-2021105117-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | claimed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021105117-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105117-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | KDM4E 1315/4885RAB9A 599/4885KMT2A 2132/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | KDM4E 1315/4885RAB9A 599/4885KMT2A 2132/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | KDM4E 1315/4885RAB9A 599/4885KMT2A 2132/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | KDM4E 1315/4885RAB9A 599/4885KMT2A 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.